C12N 2740/13061
Methods of inactivation or attenuation
C12N2740/13061 (Methods of inactivation or attenuation) appears on 35 US grants and 27 published applications in this corpus.
Search patents in C12N- Granted patents
- 35
- Published applications
- 27
- Assignees
- 27
- Inventors
- 67
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 3 |
| 2003 | 1 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 2 | 2 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 3 |
| 2023 | 1 | 1 |
| 2024 | 2 | 3 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Alternate detergents for viral inactivation9 Jun 2026US 12,649,907 B2Amgen Inc.
- Viral inactivation methods for continuous manufacturing of antibodies22 Oct 2024US 12,123,028 B2Bayer HealthCare LLC
- Viral clearance by low pH hold3 Sep 2024US 12,077,782 B2Regeneron Pharmaceuticals, Inc.
- Methods of inactivation of viruses using n-methlyglucamide and its derivatives31 Jan 2023US 11,564,392 B2Bayer HealthCare LLC
- Methods and compositions for inactivating enveloped viruses7 Jul 2020US 10,702,603 B2Biogen MA Inc.
- Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies22 Jan 2026US 2026/0022185 A1Kiniksa Pharmaceuticals, GmbH
- Viral clearance by low ph hold21 Nov 2024US 2024/0384243 A1Regeneron Pharmaceuticals, Inc.
- Continuous flow, high throughput apparatus and method for inactivating viruses and pathogens in human plasma24 Oct 2024US 2024/0350691 A1Aphios Corporation
- Methods of inactivation of viruses using n-methylglucamide and its derivatives20 Jun 2024US 2024/0196891 A1Bayer HealthCare LLC
- Methods of inactivation of viruses using n-methylglucamide and its derivatives11 May 2023US 2023/0143494 A1Bayer HealthCare LLC
Most cited
By later US patents
- Recombination resistant retroviral helper cell and products produced thereby142US 5,124,263 AWisconsin Alumni Research Foundation · 1992
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells76US 5,686,279 ACell Genesys, Inc. · 1997
- Retroviral vectors expressing cytokines62US 5,635,399 AChiron Corporation · 1997
- Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells59US 5,834,256 ACell Genesys, Inc. · 1998
- VSV G pseusdotyped retroviral vectors54US 5,817,491 AChiron Viagene, Inc. · 1998